Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
17
|
| pubmed:dateCreated |
1999-2-26
|
| pubmed:abstractText |
The antitumoral activity of recombinant canarypox virus vectors (ALVAC) expressing murine interleukin 12 (IL-12) was evaluated in the syngeneic, nonimmunogenic murine mammary adenocarcinoma model (TS/A). Seven-day preestablished subcutaneous tumors (5- to 6-mm mean diameters) were injected on days 7, 10, 14, 17, 21, and 24 with the vector ALVAC-IL12 at 2.5 x 10(5) TCID50 (50% tissue culture infective dose). Total tumor regression occurred in 40 to 50% of the treated mice. Furthermore, 100% of the cured mice were protected against a contralateral subsequent challenge with the TS/A parental cells on day 28. The ALVAC-IL12 treatment is not effective in nude mice, suggesting the critical role of T cells. CD4 and CD8 T cells infiltrated the tumors treated with ALVAC-IL12 in the BALB/c model. Furthermore, in vivo depletion of CD4+ T cells totally abrogated the induction of the long-term antitumoral immune response by ALVAC-IL12. Interestingly, some tumor growth inhibition was also observed with ALVAC-betaGal treatment and a vaccinal effect was found in 33% of the treated animals, suggesting an adjuvant effect of the vector itself. Other ALVAC vectors expressing murine cytokines (IL-2, GM-CSF, IFN-gamma) were evaluated in the same model. Major antitumoral activity was observed with ALVAC-GM-CSF. However, a combination of ALVAC-GM-CSF and ALVAC-IL12 had no synergistic effect. These results suggest that in vivo gene transfer with canarypox virus expressing IL-12 may provide an effective and safe strategy for the treatment of human cancers.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1043-0342
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
20
|
| pubmed:volume |
9
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2481-92
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9853515-Adenocarcinoma,
pubmed-meshheading:9853515-Animals,
pubmed-meshheading:9853515-Avipoxvirus,
pubmed-meshheading:9853515-CD4-Positive T-Lymphocytes,
pubmed-meshheading:9853515-Cell Division,
pubmed-meshheading:9853515-Cercopithecus aethiops,
pubmed-meshheading:9853515-Female,
pubmed-meshheading:9853515-Gene Transfer Techniques,
pubmed-meshheading:9853515-Genetic Vectors,
pubmed-meshheading:9853515-Injections, Intralesional,
pubmed-meshheading:9853515-Interleukin-12,
pubmed-meshheading:9853515-Luciferases,
pubmed-meshheading:9853515-Lymphocyte Depletion,
pubmed-meshheading:9853515-Mammary Neoplasms, Experimental,
pubmed-meshheading:9853515-Mice,
pubmed-meshheading:9853515-Mice, Inbred BALB C,
pubmed-meshheading:9853515-Mice, Nude,
pubmed-meshheading:9853515-Vero Cells
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity.
|
| pubmed:affiliation |
Department of Tumor Biology, Centre Léon Bérard, Lyon, France.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|